Substance / Medication

Famotidine

Overview

Active Ingredient
famotidine
RxNorm CUI
4278

Indications

Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: Famotidine tablets are indicated in adults for the: active duodenal ulcer (DU). active gastric ulcer (GU). symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of duodenal ulcer recurrence.

Labeler: REMEDYREPACK INC.Updated: 2026-02-17T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H2) receptor antagonists.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

14 trials linked to this intervention

14
Total Trials
2
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis.
Cheema Huzaifa Ahmad, Shafiee Arman, Athar Mohammad Mobin Teymouri et al. · J Infect · 2023
PMID: 36462586Meta-AnalysisFull text (PMC)
Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis.
Chiu Leonard, Shen Max, Lo Chun-Han et al. · PLoS One · 2021
PMID: 34735523Meta-AnalysisFull text (PMC)
Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review.
Chenchula Santenna, Ray Avik, Sadasivam Balakrishnan · Drug Res (Stuttg) · 2021
PMID: 33757133Meta-Analysis
The effect of the use of omeprazole versus famotidine on the kidney transplant function: a randomized controlled study.
Miedziaszczyk Miłosz, Karczewski Marek, Idasiak-Piechocka Ilona · Sci Rep · 2025
PMID: 39805983RCTFull text (PMC)
Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled Trial.
Leary Peter J, Rayner Samuel G, Branch Kelley R H et al. · Chest · 2025
PMID: 39761829RCTFull text (PMC)
Pharmacodynamics Between a Dual Delayed-Release Formulation of Low-Dose Esomeprazole and Famotidine in Healthy Korean Subjects.
Choi Young-Sim, Hwang Jun Gi, Kim Jae-Won et al. · Clin Ther · 2024
PMID: 39033046RCT
Efficacy of Omitting H2 Antagonists versus Famotidine in Taxane Hypersensitivity Reactions Prophylaxis: A Randomized, Prospective, Open-Label, Controlled Trial.
Chantharakhit Chaichana, Ruchakorn Tanarat, Theeratrakul Pathra et al. · Asian Pac J Cancer Prev · 2024
PMID: 39733426RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Famotidine (substance)
SNOMED CT
387211002
UMLS CUI
C0015620
RxNorm CUI
4278
Labeler
REMEDYREPACK INC.

Clinical Data

This intervention maps to 5 entities in the Ltrl knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
14
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.